Adverum Biotechnologies (ADVM) Highlights New Interim Data from Cohorts 1 and 2 of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. MU
8. DFTX
9. HOOD
10. IBM

Go back to Adverum Biotechnologies (ADVM) Highlights New Interim Data from Cohorts 1 and 2 of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD
(NASDAQ: ADVM) Delayed: 4.36 --0 (-0%)
Previous Close $4.36    52 Week High $4.86 
Open $4.36    52 Week Low $2.74 
Day High $4.36    P/E N/A 
Day Low $4.36    EPS $0.00 
Volume 12,144